N/A
Manufactured by Eli Lilly and Company
51,523 FDA adverse event reports analyzed
Last updated: 2026-05-19
Taltz is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Eli Lilly and Company. The most commonly reported adverse reactions for Taltz include INJECTION SITE PAIN, DRUG INEFFECTIVE, PSORIASIS, INJECTION SITE ERYTHEMA, INJECTION SITE REACTION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for Taltz.
Out of 36,290 classified reports for Taltz:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 51,523 FDA FAERS reports that mention Taltz. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include INJECTION SITE PAIN, DRUG INEFFECTIVE, PSORIASIS, INJECTION SITE ERYTHEMA, INJECTION SITE REACTION, INJECTION SITE SWELLING. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Eli Lilly and Company in connection with Taltz. Always verify the specific product and NDC with your pharmacist.
Explore other medications manufactured by Eli Lilly and Company and compare their safety profiles:
The following drugs share commonly reported adverse reactions with Taltz: